
Voyager Therapeutics, Inc.
NASDAQ:VYGR
Overview | Financials
Company Name | Voyager Therapeutics, Inc. |
Symbol | VYGR |
Currency | USD |
Price | 3.43 |
Market Cap | 189,803,852 |
Dividend Yield | 0% |
52-week-range | 2.75 - 9.55 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Alfred W. Sandrock Jr., M.D., Ph.D. |
Website | https://www.voyagertherapeutics.com |
An error occurred while fetching data.
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD